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Abstract
Cetuximab, a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR), is currently approved for the
treatment of several types of solid tumors. We previously showed that cetuximab can inhibit hypoxia-inducible factor-1
alpha (HIF-1a) protein synthesis by inhibiting the activation of EGFR downstream signaling pathways including Erk, Akt, and
mTOR. 1, 9-pyrazoloanthrone (1, 9 PA) is an anthrapyrazolone compound best known as SP600125 that specifically inhibits
c-jun N-terminal kinase (JNK). Here, we report 1, 9 PA can downregulate HIF-1a independently of its inhibition of JNK. This
downregulatory effect was abolished when the oxygen-dependent domain (ODD) of HIF-1a (HIF-1a-DODD, the domain
responsible for HIF-1a degradation) was experimentally deleted or when the activity of HIF-1a prolyl hydroxylase (PHD) or
the 26S proteasomal complex was inhibited, indicating that the 1, 9 PA downregulates HIF-1a by promoting PHD-
dependent HIF-1a degradation. We found that the combination of 1, 9 PA and cetuximab worked synergistically to induce
apoptosis in cancer cells in which cetuximab or 1, 9 PA alone had no or only weak apoptotic activity. This synergistic effect
was substantially decreased in cancer cells transfected with HIF-1a-DODD, indicating that downregulation of HIF-1a was the
mechanism of this synergistic effect. More importantly, 1, 9 PA can downregulate HIF-1a in cancer cells that are insensitive
to cetuximab-induced inhibition of HIF-1a expression due to overexpression of oncogenic Ras (RasG12V). Our findings
suggest that 1, 9 PA is a lead compound of a novel class of drugs that may be used to enhance the response of cancer cells
to cetuximab through a complementary effect on the downregulation of HIF-1a.
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Introduction
The epidermal growth factor receptor (EGFR) plays several
important roles in the development and progression of many types
of solid tumors [1]. Over the past two decades, novel cancer
therapies targeting EGFR have been developed and extensively
studied [2,3]. Recent clinical studies have demonstrated an
objective response in patients with several types of cancers treated
either by blocking EGFR with monoclonal antibodies (cetuximab,
panitumumab, etc.) or by inhibiting EGFR tyrosine kinase activity
with small-molecule inhibitors (gefitinib, erlotinib, etc.) [4–9].
These studies led to the regulatory approval of these EGFR-
targeting agents for treating colorectal, lung, and head and neck
cancers in combination with conventional chemotherapy or
radiotherapy; however, despite the objective responses, the overall
response rate of patients treated with EGFR-targeted therapy is
low, particularly when these EGFR-targeting agents are used as
monotherapies [10–12]. Furthermore, many patients with tumors
expressing or even highly expressing EGFR may not have an
optimal response to treatment with the EGFR-targeting agents [3].
For example, in patients with colorectal cancer, only 20–30% of
patients had disease that responded to EGFR-blocking antibodies
[4]. Among the 70–80% of patients with nonresponsive disease,
30–35% had K-Ras mutations, 20% had B-Raf and PI3K
mutations, and the rest had other aberrations [13]. Thus, although
EGFR plays important roles in tumorigenesis, cancer cells are
genetically unstable and can elude the effect of EGFR-targeted
therapy through several well-characterized and some not-yet-
known resistance mechanisms. Much ongoing research is focused
on the development of novel combinatorial therapies targeting
EGFR and molecules in EGFR downstream signaling pathways in
an attempt to overcome these resistance mechanisms.
We previously reported that cetuximab can markedly down-
regulate the high basal levels of hypoxia-inducible factor-1 alpha
(HIF-1a) by inhibiting HIF-1a protein synthesis in cancer cell lines
that are sensitive to EGFR inhibition [14,15]. We showed that
inhibition of HIF-1a is required, although it may not be sufficient,
to mediate the response of cancer cells to EGFR-targeted therapy
[14–17]. Knockdown of HIF-1a by RNA interference (RNAi)
remarkably sensitized cancer cells with oncogenic Ras mutations or
those with PTEN inactivation or deletion to cetuximab treatment
[16]. In contrast, overexpression of HIF-1a in cancer cells that
were originally sensitive to the treatment conferred substantial
resistance to anti-EGFR therapy [16]. These findings suggest that
directly targeting HIF-1a may bypass several known cetuximab-
resistance mechanisms, such as mutational activation of oncogenes
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downstream pathways and/or alternative activation of these
downstream pathways by other growth factor receptors. Novel
combination approaches to targeting EGFR and HIF-1a may,
therefore, result in an improved therapeutic response in patients.
Several strategies for targeting HIF-1a or its upstream
regulators or downstream target genes have been tested in recent
years [18]. Approaches to directly targeting HIF-1a function
include inhibiting HIF-1a gene expression using antisense or RNA
interference or inhibiting the transcriptional activity of the HIF-
1a/b heterodimer by interfering with its interaction with DNA or
cofactors. These approaches have been mainly tested experimen-
tally, given that they are difficult to test clinically with currently
available technology. Alternatively, the HIF-1a protein can be
targeted indirectly by regulating its protein synthesis or stability
using pharmacologic strategies that can be tested clinically [19].
In our effort to find novel small-molecule lead compounds that
have anti-HIF-1a activity and that may be further optimized for
combination with cetuximab to enhance therapeutic effects in
cancer cells, we discovered that 1, 9-pyrazoloanthrone (1, 9 PA),
which is an anthrapyrazolone best known as SP600125 that
specifically inhibits c-Jun N-terminal kinase (JNK) [20,21], can
strongly downregulate HIF-1a in multiple cancer cell lines. In this
study, we studied the relationship between 1, 9 PA’s known
activity of inhibiting JNK and its newly discovered activity of
downregulating HIF-1a. We also explored the biochemical
mechanisms through which 1, 9 PA downregulates HIF-1a.
Lastly, we performed proof-of-evidence experiments to test our
hypothesis that treating cancer cells with a combination of
cetuximab and 1, 9 PA can enhance the antitumor activity of
and sensitize cancer cells to cetuximab treatment. Our findings
justify the development of new derivatives of 1, 9 PA that may be
used in combination with cetuximab for cancer treatment through
complementary downregulation of HIF-1a without concomitant
inhibition of JNK.
Results
1, 9 PA downregulates HIF-1a independent of inhibiting
JNK
In this study, we found that, in addition to inhibiting c-Jun
phosphorylation in a dose-dependent manner, 1, 9 PA markedly
reduced the total HIF-1a protein level in A431 vulvar squamous
carcinoma cells as early as 15 min after treatment, whereas 1, 9
PA-induced inhibition of JNK was detected at a later time point
(Figure 1A). This suggests that 1, 9 PA’s downregulatory effect on
HIF-1a is independent of its inhibitory effect on JNK. The
compound also induced a transient increase in the levels of
activation-specific phosphorylation of Akt on both T308 and S473,
as well as a sustained and gradual increase in the level of
phosphorylated Erk in the cells, which are temporally correlated
with the recovery of HIF-1a level starting from approximately 4 h
after treatment (Figure 1A).
The treatment-induced downregulation of HIF-1a and com-
pensatory increase in cell signaling were also 1, 9 PA dose-
dependent (Figure 1B). The minimum dose of 1, 9 PA necessary to
downregulate HIF-1a was between 1.25 and 2.5 mM, which was
slightly higher than the minimum dose required to effectively
reduce c-Jun phosphorylation through inhibition of JNK (between
0.6 and 1.25 mM; Figure 1B), which further suggests that the newly
discovered downregulatory effect of 1, 9 PA on HIF-1a is
independent of its known inhibitory effect on JNK.
To confirm this observation, we treated the same cells with 1-
methyl-1, 9 PA, a structural analogue of 1, 9 PA that has been
used as a negative control for 1, 9 PA in literature because it does
not inhibit JNK. We confirmed that 1-methyl-1, 9 PA did not
reduce c-Jun phosphorylation in A431 cells compared with 1, 9
PA; however, it was equally effective at downregulating HIF-1a in
these cells (Figure 1C). On the other hand, transfection of A431
cells with either a constitutively active SEK1, which activates JNK,
or with dominant-negative SEK1 or dominant-negative MEKK1,
both of which deactivate JNK, did not affect the level of HIF-1a in
the cells (Figure 1D). These additional control experiments
provided strong evidence that inhibition of JNK alone had no
effect on the level of HIF-1a in the cell model examined.
Figure 1E shows that treatment of A431 cells with either 1, 9 PA
or 1-methyl-1, 9 PA, or knockdown of HIF-1a expression by
RNAi led to a compensatory increase in the level of phosphor-
ylated Erk in these cells, further supporting the conclusion that the
increase in cell signaling after 1, 9 PA treatment is a compensatory
response that is likely related to the downregulation of HIF-1a but
not to the inhibition of JNK.
In addition to A431 vulvar squamous carcinoma cells, we found
that 1, 9 PA could downregulate HIF-1a in PC3 prostate cancer
cells, MDA468 breast cancer cells, MCF7 breast cancer cells
transfected with a high level of HER2, and H3255 and HCC827
non-small cell lung cancer cells (Figure 1F). Taken together, these
findings strongly indicate that 1, 9 PA can downregulate HIF-1a in
human cancer cells through a mechanism(s) that is independent of
the mechanism(s) by which it inhibits JNK. These findings also
suggest that cells respond to 1, 9 PA or 1-methyl-1, 9 PA-induced
downregulation of HIF-1a or RNAi-mediated HIF-1a silencing
through a compensatory response of activation of cell signaling
pathways that are known to increase HIF-1a expression [22–26].
1, 9 PA decreases the HIF-1a level by promoting
ubiquitination of HIF-1a
We then explored the mechanism(s) by which 1, 9 PA
downregulates HIF-1a. HIF-1a is a highly unstable protein under
normoxic conditions because it possesses the oxygen-dependent
domain (ODD) that is subject to posttranslational regulation
through protein ubiquitination and degradation [27,28]. Because
1, 9 PA dramatically reduced the HIF-1a level in less than 15 min
(0.25 h; Figure 1A), we hypothesized that 1, 9 PA acts through a
mechanism that enhances HIF-1a protein degradation. Figure 2A
shows that, compared with vehicle control treatment of A431 cells
following blockade of new protein synthesis with cycloheximide,
treatment of the cells with 1, 9 PA markedly expedited the
degradation of HIF-1a; the degradation time was shortened from
60 min in the control cells to less than 20 min in the cells treated
with 1, 9 PA. Furthermore, 1, 9 PA-induced downregulation of
HIF-1a was completely blocked by treating the A431 cells with
MG132 (Figure 2B), which inhibits the 26S proteasomal complex,
indicating that the reduction in HIF-1a after 1, 9 PA treatment
was mediated by enhancing protein degradation.
While 1, 9 PA markedly downregulated HIF-1a under
normoxic conditions, we found that the ability of 1, 9 PA to
downregulate HIF-1a was markedly reduced when oxygen was
not available or when the cells were treated with deferoxamine
(DFO), an iron-chelating agent (Figure 3A); both O2 and Fe
2+ are
required for HIF-1a prolyl hydroxylase (PHD) activity to
hydroxylate HIF-1a for recognition by the VHL ubiquitin ligase
[29,30]. The result of treatment with DFO was similar to that of
treatment with MG132: the ubiquitinated HIF-1a was inhibited
from degradation through the proteasome pathway (Figure 3A).
These findings suggest that 1, 9 PA can directly or indirectly affect
the ubiquitination of HIF-1a [29,30].
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PA to regulate an HIF-1a mutant in which the PHD/VHL
interacting domain on HIF-1a, i.e., ODD, was deleted (HIF-1a-
DODD). As expected, while 1, 9 PA decreased the level of wild-
type HIF-1a, it did not affect the level of HIF-1a-DODD in A431
cells transiently transfected with the HIF-1a-DODD construct
(Figure 3B). We then established pooled A431 cells that stably
expressed HIF-1a-DODD and further confirmed the findings
obtained in the parental A431 cells by treating the A431 cells
expressing HIF-1a-DODD in the same manner (Figure 3C).
Together, these findings strongly support the conclusion that 1, 9
PA downregulates HIF-1a through a mechanism involving the
interaction between PHD/VHL and the ODD of HIF-1a. When
the key elements (O2,F e
2+, and 26S proteasome) required for
PHD activity to hydroxylate HIF-1a and for the subsequent VHL-
mediated ubiquitination and degradation are missing or inhibited,
or when the ODD of HIF-1a, which is the targeted domain by the
VHL ubiquitin ligase complex, is absent, 1, 9 PA loses its ability to
downregulate HIF-1a.
To obtain direct evidence that 1, 9 PA promotes the
ubiquitination of HIF-1a, we subjected the HIF-1a immunopre-
cipitated from lysates of 1, 9 PA-treated A431 cells to Western
Figure 1. 1, 9 PA downregulates HIF-1a independent of its JNK inhibitory function. (A) Temporal order and correlation of 1, 9 PA-induced
HIF-1a downregulation and JNK inhibition, and the treatment-induced compensatory activation of Akt and Erk. A431 cells were treated with 5 mM1 ,
9 PA in 0.5% FBS culture medium for the indicated time intervals. Cell lysates were then prepared for Western blotting with the antibodies shown. (B)
Dose-dependent effects of 1, 9 PA on downregulating HIF-1a, inhibiting JNK, and activating Erk. A431 cells were exposed to increasing
concentrations of 1, 9 PA for 16 h in 0.5% FBS culture medium at 37uC. Cell lysates were then prepared for Western blotting with the antibodies
shown. (C) Independence of 1, 9 PA-induced HIF-1a downregulation from its JNK inhibitory function. A431 cells were treated with increasing
concentrations of 1, 9 PA or 1-methyl-1, 9 PA for 1 h in 0.5% FBS culture medium. Cell lysates were then prepared for Western blotting with the
antibodies shown. (D) No changes in HIF-1a level after activation or inhibition of JNK. A431 cells wert transiently transfected with a control vector or
one of the constructs containing a constitutively active SEK1 S220E/T224D mutant (SEK1-CA), a dominant-negative SEK1 K129R mutant (SEK1-DN), or
a dominant-negative MEKK1 K432M mutant (MEKK1-DN) overnight. Cell lysates were then prepared for Western blotting with the antibodies shown.
(E) Compensatory activation of Erk after HIF-1a silencing in comparison with treatment by 1, 9 PA or 1-methyl-1, 9 PA. A431 cells were subjected to
knockdown of HIF-1a with specific or control siRNA, or treated with 10 mM 1, 9 PA or 1-methyl-1, 9 PA for 16 h. Cell lysates were then prepared for
Western blotting with the antibodies shown. (F) Downregulation of HIF-1a by 1, 9 PA in various cancer cell lines. Indicated cell lines were exposed to
10 or 40 mM 1, 9 PA for 1 h in 0.5% FBS culture medium. Cell lysates were then prepared for Western blotting with the antibodies shown.
doi:10.1371/journal.pone.0015823.g001
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polyubiquitinated HIF-1a was clearly increased within 10 minutes
after 1, 9 PA treatment (Figure 4A). Presence of the proteasomal
inhibitor MG132 during the 1, 9 PA treatment inhibited
ubiquitinated HIF-1a from being degraded (Figure 4B).
Taken together, our data provide strong evidence that 1, 9 PA
decreases HIF-1a through a mechanism that enhances the
interaction between the ODD of HIF-1a and the PHD/VHL/
ubiquitination complex, and thereby leads to an enhanced
degradation of HIF-1a through the proteasome pathway.
1, 9 PA synergizes with cetuximab to induce apoptosis
through co-downregulating HIF-1a
We previously showed that cetuximab downregulates HIF-1a in
cancer cells sensitive to anti-EGFR therapy through inhibition of
HIF-1a protein synthesis, which was prevented by expression of a
myristoylated Akt that is constitutively active [16]. Figure 5A
shows our current findings, which are similar to those we
previously reported; interestingly, unlike our previous findings,
expression of the constitutively active Akt did not affect 1, 9 PA-
induced downregulation of HIF-1a (Figure 5B), implicating that
the role of 1, 9 PA-induced increase in Akt activity (see Figure 1A)
was not to counteract 1, 9 PA-induced HIF-1a protein
degradation, but rather to compensate for 1, 9 PA-induced HIF-
1a protein degradation by stimulating new HIF-1a protein
synthesis.
We thus hypothesized that the combination of 1, 9 PA and
cetuximab,which caninhibit the AktandErkpathwaysandthereby
block the compensatory mechanisms, would have an additive or
even synergistic effect on the downregulation of HIF-1a. We tested
this hypothesis in 3 cancer cell lines that are sensitive to cetuximab
treatment: A431, HN5 (head and neck cancer), and DiFi (colorectal
cancer). Because DiFi cells are extremely sensitive to cetuximab,
they were treated with 2 nM cetuximab; A431 and HN5 cells,
which are not as sensitive to cetuximab as DiFi cells, were treated
with10 nMcetuximab.Figure6Ashowsthat,when anyofthe 3 cell
lines was treated with either 10 or 40 mM 1, 9 PA or cetuximab
alone, HIF-1a wasdownregulated. When thecellsweretreatedwith
both 1, 9 PA and cetuximab, HIF-1a was further downregulated.
Treating the cells with cetuximab or 1, 9 PA alone induced only
minimal or no cleavage of PARP, a marker of apoptosis; however,
the combination of cetuximab and 1, 9 PA markedly enhanced the
induction of PARP cleavage in all 3 cell lines.
We selected A431 cells to further confirm this result by using an
independent apoptosis ELISA that quantitatively measures the
Figure 2. 1, 9 PA downregulates HIF-1a by enhancing HIF-1a
protein degradation. (A) Reduced HIF-1a protein stability in the
presence of 1, 9 PA (1, 9 PA). A431 cells were treated with 10 mM
cycloheximide (CHX) plus 10 mM 1, 9 PA or DMSO vehicle control in
0.5% FBS culture medium for up to 60 min at 37uC. Cell lysates were
prepared after treatment at each time point and analyzed by Western
blotting with the antibodies shown. (B) Inhibition of 1, 9 PA-induced
HIF-1a degradation by the proteasomal inhibitor MG132. A431 cells
were treated with 10 mM1 ,9P A ±10 mM MG132 for the indicated time
intervals. Cell lysates were prepared after treatment at each time point
and analyzed by Western blotting with the antibodies shown.
doi:10.1371/journal.pone.0015823.g002
Figure 3. 1, 9 PA downregulates HIF-1a in a PHD- and HIF-1a
ODD-dependent manner. (A) Requirement of O2 and Fe
2+ in the 1, 9
PA-induced downregulation of HIF-1a. A431 cells were untreated or
treated with 10 mM 1, 9 PA in 0.5% FBS culture medium under normoxic
conditions in the absence or presence of DFO (100 mM) or MG132
(10 mM), and under hypoxic conditions for 16 h at 37uC. Cell lysates
were then prepared for Western blotting with the antibodies shown. (B)
Role of the ODD of HIF-1a in the 1, 9 PA-induced downregulation of
HIF-1a. A431 cells were transiently transfected with the HIF-1a-DODD
construct or a control vector for 48 h and were then either untreated or
treated with the indicated concentrations of 1, 9 PA for 1 h at 37uC. Cell
lysates were then prepared for Western blotting with the antibodies
shown. (C) Resistance of A431/HIF-1a-DODD cells to the 1, 9 PA-
induced downregulation of HIF-1a. A431 cells stably expressing the HIF-
1a-DODD construct were treated as described in (A). Cell lysates were
then prepared for Western blotting with the antibodies shown.
doi:10.1371/journal.pone.0015823.g003
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after apoptosis (Figure 6B). 1, 9 PA alone at concentrations of 10
and 40 mM did not noticeably increase the level of apoptosis;
cetuximab alone only moderately increased the level of histone-
associated DNA fragmentation in the cytoplasm. However, we
found that the combination treatment significantly increased the
level of apoptosis (p,0.01). To further confirm whether the
induction of apoptosis seen with the combination treatment was
mediated by the complementary effects on the downregulation of
HIF-1a by these 2 agents, we repeated the experiments in A431
cells expressing HIF-1a-DODD cells. Figure 6C shows that,
compared with its effect in control vector–transfected A431neo
cells, the combination treatment had a markedly lower effect on
the PARP cleavage in A431/HIF-1a-DODD cells. The effect of 1,
9 PA on the downregulation of endogenous HIF-1a was also
reduced in A431/HIF-1a-DODD cells compared with A431neo
cells. These data indicate that downregulation of HIF-1a was the
mechanism for the synergic effect of the combination of 1, 9 PA
and cetuximab.
1, 9 PA overcomes oncogenic Ras-induced cetuximab
resistance
Oncogenic mutation of Ras has been shown to be a major
mechanism of cetuximab resistance in patients with colorectal
cancer [10]. We previously showed as a proof of concept that
knockdown of HIF-1a through RNAi substantially restores the
sensitivity of A431 cells transfected with an oncogenic H-Ras
(G12V) mutant to cetuximab treatment [16]. To further prove this
novel concept, we examined the effect of 1, 9 PA alone and in
combination with cetuximab in A431 cells transfected with Ras-
G12V (A431/RasG12V). Figure 7A shows that, compared with
control vector–transfected A431neo cells, A431/RasG12V cells
had a higher basal level of Akt phosphorylation and were resistant
to cetuximab-induced inhibition of Akt phosphorylation, down-
regulation of HIF-1a, and cleavage of PARP. In addition, 1, 9 PA
alone inhibited both the basal and Ras-induced upregulation of
Akt phosphorylation and downregulated HIF-1a in both A431neo
and A431/RasG12V cells, but it had no detectable effect on the
induction of PARP cleavage in either cell line. The combination of
1, 9 PA and cetuximab, however, markedly increased cleavage of
PARP in both A431neo and A431/RasG12V cells. The cleavage
of PARP in A431/RasG12V cells is particularly important,
because cetuximab alone was unable to induce PARP cleavage
in these cells owing to the expression of oncogenic Ras; whereas
the combination treatment in the A431/RasG12V cells resulted in
a level of PARP cleavage that was similar to the level of PARP
cleavage in A431neo cells, indicating a synergism between 1, 9 PA
and cetuximab in inducing apoptosis in cetuximab-resistant cancer
cells.
To obtain further evidence at a cellular level to support the pro-
apoptotic effect of the combination treatment, we performed a
conventional cell growth and survival assay comparing the
cetuximab dose-dependent effect with and without 1, 9 PA in
A431neo and A431/RasG12V cells. We found that 1, 9 PA
sensitized both A431neo and A431/RasG12V cells to cetuximab
(Figure 7B). The addition of 1, 9 PA to cetuximab shifted the IC50
of cetuximab from 3–10 nM to less than 1 nM in A431neo cells,
and more importantly, it achieved an IC50 of 3 nM for cetuximab
in A431/RasG12V cells; in contrast, the IC50 of cetuximab alone
was not reached (Figure 7B), even at concentrations greater than
10 nM (data not shown).
Figure 4. 1, 9 PA enhances HIF-1a ubiquitination. (A). A431 cells were treated with 10 mM 1, 9 PA for indicated time period. Cell lysates were
prepared for HIF-1a immunoprecipitation, followed by Western blotting of the immunoprecipitates with antibodies directed against ubiquitin (top),
HIF-1a, and b-actin. (B) A431 cells were untreated or treated with 10 mM 1, 9 PA in the presence of 10 mM MG132 for 1 h in 0.5% FBS medium. HIF-1a
was immunoprecipitated followed by Western blot analysis with an anti-HIF-1a antibody.
doi:10.1371/journal.pone.0015823.g004
Figure 5. Differential effect of constitutively active Akt on cetuximab and 1, 9 PA-induced downregulation of HIF-1a. A431 cells were
transiently transfected with a control vector or a myristoylated Akt (Myr-Akt) for 24 h in 0.5% FBS medium. The vector- or Myr-Akt–transfected cells
were then treated with either 20 nM cetuximab or PBS overnight (A), or with 10 mM 1, 9 PA or DMSO vehicle control for 1 h (B). After treatment, cell
lysates were prepared for Western blotting with the antibodies shown.
doi:10.1371/journal.pone.0015823.g005
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appreciably inhibit VEGF production compared to treating these
cells with cetuximab alone; adding 1, 9 PA did not further lower
the level of VEGF production that was inhibited by cetuximab
(Figure 7C). Interestingly, however, when A431 cells became
resistance to cetuximab-induced inhibition of VEGF production
due to expression of the oncogenic RasG12V, the addition of 1, 9
PA significantly lowered the level of VEGF production (p,0.01).
Lastly, to determine whether 1, 9 PA can also sensitize cancer
cells with naturally occurring Ras mutations, we examined the
effect of the combination of 1, 9 PA and cetuximab on GEO
colorectal cancer cells, which are known to have mutated Ras [31].
However, despite bearing a mutated Ras on exon 2, GEO cells
responded to 1, 9 PA and cetuximab in a similar fashion as A431
cells did. 1, 9 PA led to a compensatory increase in the level of
phosphorylated Erk after overnight treatment (16 h) in both A431
and GEO cells, which was reduced in the presence of cetuximab.
The combination of these 2 agents enhanced PARP cleavage in
both types of cells (Figure 7D) and sensitized GEO cells to
cetuximab-induced inhibition of cell growth and survival
(Figure 7E).
In summary, our findings indicate that 1, 9 PA can sensitize cancer
cells to cetuximab-mediated anti-EGFR therapy by downregulating
HIF-1a and can enhance cellular response to cetuximab treatment in
cancer cells bearing oncogenic Ras mutations.
Discussion
Here, we report 2 important findings, which, to our knowledge,
have not been previously reported. First, we found that 1, 9 PA
promotes HIF-1a ubiquitination and degradation, and this
function of 1, 9 PA is independent of its well-known function as
an inhibitor of JNK. Second, we found that 1, 9 PA sensitizes
cancer cells to cetuximab treatment, and this effect of 1, 9 PA is
dependent on the ability of 1, 9 PA to downregulate HIF-1a.
Furthermore, we showed that 1, 9 PA can enhance the response of
cancer cells expressing an oncogenic Ras, which is a well-
characterized cetuximab-resistance mechanism in colorectal
cancer patients, to cetuximab [10–12,32–37]. Thus, our work
establishes an important principle for the first time that 1, 9 PA, as
a lead compound, can sensitize cancer cells to cetuximab-mediated
anti-EGFR therapy. Development of new derivatives of 1, 9 PA
that will retain the activity of downregulating HIF-1a but will not
affect its inhibitory effect on JNK activity is warranted.
Our studies showed that 1, 9 PA downregulates HIF-1a by
enhancing HIF-1a degradation; however, the exact molecular
target for this novel function of 1, 9 PA remains unknown.
Anthrapyrazolones as a class are capable of interacting with DNA,
which may affect HIF-1a mRNA stability or synthesis; however,
such an interaction with DNA is not supposedly dependent on
PHD and the structural requirement of the ODD of HIF-1a.
Because 1, 9 PA apparently accelerates degradation of HIF-1a by
enhancing HIF-1a ubiquitination, one possibility is that 1, 9 PA
activates a pathway that enhances ubiquitination of HIF-1a. This
could be mediated by the increased expression and/or activity of
related proteins, such as PHD, the VHL ubiquitin ligase, a protein
that activates PHD or VHL, or a protein that deactivates an
inhibitor of VHL or PHD. Other possible mechanisms by which 1,
9 PA promotes the degradation of HIF-1a are targeting other
proteins indirectly affecting HIF-1a degradation through the
Figure 6. Combination of 1, 9 PA and cetuximab induces apoptosis through downregulation of HIF-1a. (A) Induction of PARP cleavage
by the combination of 1, 9 PA and cetuximab. A431, HN5, and DiFi cells were untreated or treated with cetuximab (10 nM for A431 and HN5 cells and
2 nM for DiFi cells for 16 h), 1, 9 PA (10 mMo r4 0mM added the last hour before cell lysis), or both in 0.5% FBS culture medium. Cell lysates were
prepared and analyzed by Western blotting with the antibodies shown. (B) Increased induction of apoptosis by the combination of 1, 9 PA and
cetuximab. A431 cells were treated as described in (A). Cell lysates were prepared and analyzed by apoptosis ELISA. The relative absorbance values
are plotted. The p value was ,0.01 when comparing the level of apoptosis by 1, 9 PA alone (10 or 40 mM) or cetuximab alone with that of apoptosis
by combination of the 2 agents (note: only the p values comparing 10 mM 1, 9 PA alone and in combination with cetuximab are shown). (C)
Dependence of induction of apoptosis by the combination of 1, 9 PA and cetuximab on HIF-1a downregulation. A431neo and A431/HIF-1a-DODD
cells were treated as indicated, and the cell lysates were prepared and analyzed as described in (A).
doi:10.1371/journal.pone.0015823.g006
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identifying the molecular target(s), interaction with which 1, 9 PA
promotes HIF-1a ubiquitination, are needed to develop this lead
compound into a new class of anticancer agents.
Our current work showing that the combination of 1, 9 PA and
cetuximab induces apoptosis in various cancer cells has strong
implications for clinical application. There are 2 important
potential concerns that are worth discussing. First, we found that
there was quick activation of compensatory cell signaling after 1, 9
PA treatment, which can stimulate new HIF-1a protein synthesis
and quickly revert the lowered HIF-1a level to its original level
before treatment. Second, 1, 9 PA-mediated HIF-1a ubiquitina-
tion requires the presence of oxygen but most solid tumors are
hypoxic. These 2 potential problems can be solved by our
proposed strategy of combining 1, 9 PA and cetuximab. Here, we
demonstrated that cetuximab can inhibit the cell signaling
activated in the cells as a compensatory response after 1, 9 PA
treatment; the combination treatment resulted in synergistic effects
on induction of cell death via apoptosis. In addition, although
hypoxia is common in most solid tumors, tumors are not 100%
hypoxic. Some tumor areas, particularly those located at the
periphery of a solid tumor, are not hypoxic. Importantly,
cetuximab can inhibit HIF-1a protein synthesis in both normoxic
and hypoxic cells [16]. Together, these considerations strongly
justify the combination of cetuximab with new derivatives of 1, 9
PA in future preclinical (animal studies) and clinical studies.
Exploration of new strategies combining EGFR inhibitors with
agents targeting one or more EGFR downstream targets, such as
signal transduction molecules in the PI3K/Akt/mTOR pathway,
has been an active area of research in recent years [38]. Based on
our current and recent findings [14–17], we propose that an
alternative co-targeting of EGFR with one or more of the critically
important downstream effector molecules, such as HIF-1a, may be
a better approach. The advantage of directly targeting critical
transcription factors is that it bypasses several intermediate signal
transduction molecules in the EGFR downstream signaling
pathways that are often aberrantly regulated by mutations in
cancer cells. The complementarity between the mechanisms used
by cetuximab (inhibition of HIF-1a protein synthesis) and 1, 9 PA
(promotion of HIF-1a protein degradation) for downregulating
HIF-1a offers a strong rationale for a new combination to
effectively inhibit the HIF-1 transcription factor-mediated cellular
effects. The results shown in our current study clearly demonstrate
a strong induction of apoptosis in cancer cells by combination
Figure 7. 1, 9 PA enhances responses of cancer cells expressing an oncogenic Ras mutant to cetuximab. (A) Effect of 1, 9 PA and
cetuximab, either alone or in combination, on the HIF-1a level and induction of apoptosis. A431neo and A431/RasG12V cells were untreated or
treated with cetuximab (10 nM for 16 h), 10 mM 1, 9 PA (added the last hour before cell lysis), or both in 0.5% FBS culture medium. Cell lysates were
prepared and analyzed by Western blotting with the antibodies shown. (B) 1, 9 PA-mediated sensitization to cetuximab-induced growth inhibition.
A431neo and A431/RasG12V cells were treated with increasing concentrations of cetuximab 65 mM 1, 9 PA in 0.5% FBS culture medium for 5 days.
After treatment, the cells were subjected to an MTT assay. The optical density values of the treated groups were normalized to the values of the
control groups (with or without 1, 9 PA treatment) and expressed as a percentage of respective control. The percentage of surviving cells was plotted
as a function of treatment with increasing concentrations of cetuximab. The differences in cell survival between the two groups were statistically
significant (p,0.01) when the concentrations of cetuximab were greater than 0.625 nM in A431neo cells and 1.25 nM in A431/RasG12V cells. (C) 1, 9
PA-mediated sensitization to cetuximab-induced inhibition of VEGF production. A431neo and A431/RasG12V cells were untreated or treated with
10 nM cetuximab, 10 mM 1, 9 PA, or both in 0.5% FBS culture medium for 16 h. The VEGF secreted into the conditioned media by the cells was
measured by ELISA. The p-values for indicated comparisons were shown. (D) Comparison of A431 and GEO cells to treatment with 1, 9 PA and
cetuximab, either alone or in combination. A431 and GEO cells were treated as described in (A). Cell lysates were prepared and analyzed by Western
blotting with the antibodies shown. (E). 1, 9 PA-mediated sensitization GEO cells to cetuximab-induced growth inhibition. GEO cells were treated with
increasing concentrations of cetuximab 65 mM 1, 9 PA in 0.5% FBS culture medium for 5 days. After treatment, the cells were subjected to an MTT
assay. The data were processed as described in (B). The differences in cell survival between the two groups were statistically significant (p,0.01) at all
concentrations of cetuximab tested.
doi:10.1371/journal.pone.0015823.g007
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targeting HIF-1a. Further investigation in proper animal models
with new derivatives of 1, 9 PA is needed to provide further
evidence supporting this novel strategy.
In summary, we have identified a novel activity of 1, 9 PA—
downregulation of HIF-1a—that is independent of its JNK
activity, and we have elucidated the relevant mechanism of
action. We have also explored potential application of this novel
activity of 1, 9 PA in enhancing cancer cell response to cetuximab.
Our findings provide a strong rationale for developing new
derivatives of this lead compound that could be used in
combination with cetuximab in cancer patients to improve clinical
outcomes.
Materials and Methods
Reagents
Cetuximab was a gift from ImClone Systems (New York, NY).
1, 9 PA, 1-methy-1, 9 PA, and MG132 were purchased from
CalBiochem/EMD Chemicals, Inc. (Gibbstown, NJ). The follow-
ing antibodies were used for Western blotting and immunopre-
cipitation: HIF-1a and Ras (BD Biosciences Pharmingen, San
Diego, CA); total and S473-phosphorylated Akt, total extracellular
signal-activated kinase (Erk), total and S73-phosphorylated c-Jun,
poly(ADP-ribose) polymerase (PARP), and ubiquitin (all from Cell
Signaling Technology, Inc., Danvers, MA); T202/Y204-phos-
phorylated Erk (Santa Cruz Biotechnology, Santa Cruz, CA). All
other chemicals were purchased from Sigma-Aldrich Corp. (St.
Louis, MO).
Cell lines and cell culture
A431 vulvar squamous carcinoma cells, HN5 head and neck
cancer cells, PC3 prostate cancer cells, MDA468 and MCF7-
HER2 breast cancer cells, and H3255 and H827 non-small cell
lung cancer cells, DiFi and GEO colorectal cancer cells were
obtained and maintained as described previously [15,16,39–41].
Briefly, all cell lines were grown in Dulbecco’s modified Eagle’s
medium and Ham’s F12 medium (50:50 by volume) supplemented
with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/mL
of penicillin, and 100 mg/mL of streptomycin and maintained in a
humidified 37uC incubator with 95% air and 5% CO2. For
hypoxic cell cultures, cells were placed in an airtight chamber that
was flushed with a gas mixture of 5% CO2 and 95% N2. The
oxygen concentration inside the chamber was maintained at 1%
using the Pro-Ox O2 regulator (Model 110; BioSpherix, Lacona,
NY). The hypoxic chamber was placed in the same 37uC
incubator where parallel groups of cells were incubated under
normoxic culture conditions.
cDNA constructs and transfection
cDNA constructs expressing HIF-1a-DODD, Myr-Akt, and H-
RasG12V were generated aspreviously described [16,42]. Constructs
expressing constitutively active SEK1 S220E/T224D mutant (SEK1-
CA), dominant-negative SEK1 K129R mutant (SEK1-DN), and
dominant-negative MEKK1 K432M mutant (MEKK1-DN) were
kindly provided by Dr. Jonathan Kurie (MD Anderson Cancer
Center). Transfection of the cDNA constructs into the targeted cells
was performed with Lipofectamine 2000 (Invitrogen, Inc. Carlsbad,
CA), according to the manufacturer’s instructions.
Western blotting
Cultured cells were harvested with a rubber scraper and washed
twice with cold phosphate-buffered saline (PBS). Cell pellets were
lysed and kept on ice for at least 10 min in a buffer containing
50 mM Tris (pH 7.4), 150 mM NaCl, 0.5% Nonidet P-40, 50 mM
NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 25 mg/
mL of leupeptin, and 25 mg/mL of aprotinin. The lysates were
cleared by centrifugation, and the supernatants were collected. Cell
lysates were then separated by sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis and subjected to Western blotting
with the primary antibodies and horseradish peroxidase–labeled
secondary antibodies. We visualized the signals with an enhanced
chemiluminescence detection kit (GE Healthcare, Piscataway, NJ).
Cell proliferation assay
Cells were cultured in 24-well plates with 0.5 mL of medium
per well at 37uCi naC O 2 incubator. At the end of the desired
treatment in cell culture, the cells were incubated for an additional
2 h after the addition of 50 mL/well of 10 mg/mL 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).
The cells were then lysed with a lysis buffer (500 mL/well)
containing 20% SDS in dimethyl formamide/H2O (1:1, v/v;
pH 4.7) at 37uC for at least 6 h. We determined the relative
number of surviving cells in each group by measuring the optical
density (OD) of the cell lysates at an absorbance wavelength of
570 nm. The OD value in each treatment group was then
normalized to that of untreated cells as a percentage of the OD
value of the control and plotted against the treatments.
Apoptosis assay
We measured apoptosis using an enzyme-linked immunosorbent
assay (ELISA) kit (Roche Diagnostics Corp., Indianapolis, IN) that
quantitatively measures cytoplasmic histone-associated DNA frag-
ments (mononucleosomes and oligonucleosomes) and by Western
blotting with an antibody that recognizes both uncleaved and cleaved
PARP after various treatments, as previously described [43,44].
Measurement of VEGF levels in conditioned medium
VEGF levels in the conditioned medium were measured by
ELISA (R & D Systems, Minneapolis, MN) 24 h after treatment.
Relative VEGF levels were expressed as the OD value of the
conditioned medium normalized by the number of cells of each
sample in the culture plates. Experiments were repeated twice.
Statistical analysis
Student’s t-test was used to compare the mean differences
between two groups using Statistica-6.0 software package. The
results were expressed as means 6 standard deviation. P
values,0.01 were considered statistically significant.
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